These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 33304846)

  • 21. The diagnostic value of immunohistochemically detected methylthioadenosine phosphorylase deficiency in malignant pleural mesotheliomas.
    Zimling ZG; Jørgensen A; Santoni-Rugiu E
    Histopathology; 2012 May; 60(6B):E96-105. PubMed ID: 22394205
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fluorescence in situ hybridization (FISH) provides estimates of minute and interstitial BAP1, CDKN2A, and NF2 gene deletions in peritoneal mesothelioma.
    Brich S; Bozzi F; Perrone F; Tamborini E; Cabras AD; Deraco M; Stacchiotti S; Dagrada GP; Pilotti S
    Mod Pathol; 2020 Feb; 33(2):217-227. PubMed ID: 31570769
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Utility of Methylthioadenosine Phosphorylase Compared With BAP1 Immunohistochemistry, and CDKN2A and NF2 Fluorescence In Situ Hybridization in Separating Reactive Mesothelial Proliferations From Epithelioid Malignant Mesotheliomas.
    Berg KB; Dacic S; Miller C; Cheung S; Churg A
    Arch Pathol Lab Med; 2018 Dec; 142(12):1549-1553. PubMed ID: 30059257
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Deletion status of p16 in effusion smear preparation correlates with that of underlying malignant pleural mesothelioma tissue.
    Hida T; Matsumoto S; Hamasaki M; Kawahara K; Tsujimura T; Hiroshima K; Kamei T; Taguchi K; Iwasaki A; Oda Y; Honda H; Nabeshima K
    Cancer Sci; 2015 Nov; 106(11):1635-41. PubMed ID: 26291840
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlation of MTAP Immunohistochemistry With CDKN2A Status Assessed by Fluorescence In Situ Hybridization and Clinicopathological Features in CNS WHO Grade 2 and 3 Meningiomas: A Single Center Cohort Study.
    Sasaki S; Takeda M; Hirose T; Fujii T; Itami H; Uchiyama T; Morita K; Matsuda R; Yamada S; Nakagawa I; Ohbayashi C
    J Neuropathol Exp Neurol; 2022 Jan; 81(2):117-126. PubMed ID: 34897475
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HEG1, BAP1, and MTAP are useful in cytologic diagnosis of malignant mesothelioma with effusion.
    Hiroshima K; Wu D; Hamakawa S; Tsuruoka S; Ozaki D; Orikasa H; Hasegawa M; Koh E; Sekine Y; Yonemori Y; Nabeshima K; Tsuji S; Miyagi Y; Imai K
    Diagn Cytopathol; 2021 May; 49(5):622-632. PubMed ID: 32441895
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genomic-based ancillary assays offer improved diagnostic yield of effusion cytology with potential challenges in malignant pleural mesothelioma.
    Kinoshita Y; Hamasaki M; Matsumoto S; Yoshimura M; Sato A; Tsujimura T; Kamei T; Kawahara K; Nabeshima K
    Pathol Int; 2020 Sep; 70(9):671-679. PubMed ID: 32542810
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesothelioma.
    Chung CT; Santos Gda C; Hwang DM; Ludkovski O; Pintilie M; Squire JA; Tsao MS
    J Clin Pathol; 2010 Jul; 63(7):630-4. PubMed ID: 20591913
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low homozygous/high heterozygous deletion status by p16 FISH correlates with a better prognostic group than high homozygous deletion status in malignant pleural mesothelioma.
    Hamasaki M; Matsumoto S; Abe S; Hamatake D; Kamei T; Hiroshima K; Kawahara K; Sato A; Tsujimura T; Nakatani Y; Yoshida Y; Iwasaki A; Nabeshima K
    Lung Cancer; 2016 Sep; 99():155-61. PubMed ID: 27565933
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Use of Immunohistochemistry, Fluorescence
    Rozitis E; Johnson B; Cheng YY; Lee K
    Front Oncol; 2020; 10():1742. PubMed ID: 33014860
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 5-hmC loss is another useful tool in addition to BAP1 and MTAP immunostains to distinguish diffuse malignant peritoneal mesothelioma from reactive mesothelial hyperplasia in peritoneal cytology cell-blocks and biopsies.
    Alsugair Z; Kepenekian V; Fenouil T; Glehen O; Villeneuve L; Isaac S; Hommell-Fontaine J; Benzerdjeb N
    Virchows Arch; 2022 Jul; 481(1):23-29. PubMed ID: 35575935
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BAP1 immunohistochemistry and p16 FISH results in combination provide higher confidence in malignant pleural mesothelioma diagnosis: ROC analysis of the two tests.
    Hida T; Hamasaki M; Matsumoto S; Sato A; Tsujimura T; Kawahara K; Iwasaki A; Okamoto T; Oda Y; Honda H; Nabeshima K
    Pathol Int; 2016 Oct; 66(10):563-570. PubMed ID: 27614970
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sarcomatoid mesothelioma diagnosed in a patient with mesothelioma in situ: a case report on morphologic differences after 9-month interval with details analysis of cytology in early-stage mesothelioma.
    Yoshida M; Jimbo N; Tsukamoto R; Itoh T; Kawahara K; Mitsui S; Tanaka Y; Maniwa Y
    Diagn Pathol; 2023 Nov; 18(1):126. PubMed ID: 38017544
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma.
    McGregor SM; McElherne J; Minor A; Keller-Ramey J; Dunning R; Husain AN; Vigneswaran W; Fitzpatrick C; Krausz T
    Hum Pathol; 2017 Feb; 60():86-94. PubMed ID: 27771374
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sarcomatoid mesothelioma originating from mesothelioma in situ: are methylthioadenosine phosphorylase loss and CDKN2A homozygous deletion poor prognostic factors for preinvasive mesothelioma?
    Nishikubo M; Jimbo N; Tanaka Y; Tachihara M; Itoh T; Maniwa Y
    Virchows Arch; 2022 Aug; 481(2):307-312. PubMed ID: 35043235
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evidence-based diagnostic performance of novel biomarkers for the diagnosis of malignant mesothelioma in effusion cytology.
    Girolami I; Lucenteforte E; Eccher A; Marletta S; Brunelli M; Graziano P; Pisapia P; Malapelle U; Troncone G; Scarpa A; Huang T; Pantanowitz L
    Cancer Cytopathol; 2022 Feb; 130(2):96-109. PubMed ID: 34478240
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reliability assessment of methylthioadenosine phosphorylase immunohistochemistry as a surrogate biomarker for CDKN2A homozygous deletion in adult-type IDH-mutant diffuse gliomas.
    Gundogdu F; Babaoglu B; Soylemezoglu F
    J Neuropathol Exp Neurol; 2024 Jan; 83(2):107-114. PubMed ID: 38109891
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular Characterization of Mesothelioma: Impact of Histologic Type and Site of Origin on Molecular Landscape.
    Dagogo-Jack I; Madison RW; Lennerz JK; Chen KT; Hopkins JF; Schrock AB; Ritterhouse LL; Lester A; Wharton KA; Mino-Kenudson M; Danziger N; Hung YP; Mata DA; Ross JS
    JCO Precis Oncol; 2022 Jun; 6():e2100422. PubMed ID: 35704798
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Concordance between CDKN2A homozygous deletion and MTAP immunohistochemical loss in fluoroedenite-induced pleural mesothelioma: An immunohistochemical and molecular study on a single-institution series.
    Broggi G; Massimino M; Failla M; Filetti V; Rapisarda V; Ledda C; Lombardo C; Loreto C; Vigneri P; Caltabiano R
    Pathol Res Pract; 2024 Jul; 259():155350. PubMed ID: 38781764
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Morphology of 9p21 homozygous deletion-positive pleural mesothelioma cells analyzed using fluorescence in situ hybridization and virtual microscope system in effusion cytology.
    Matsumoto S; Nabeshima K; Kamei T; Hiroshima K; Kawahara K; Hata S; Marukawa K; Matsuno Y; Taguchi K; Tsujimura T
    Cancer Cytopathol; 2013 Aug; 121(8):415-22. PubMed ID: 23450849
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.